TNFRSF12A expression in stomach adenocarcinoma and its preliminary role in predicting immunotherapy response

BackgroundTNFRSF12A is abnormally expressed in various malignancies, especially in stomach adenocarcinoma (STAD), which is related to tumor invasiveness and prognosis of patients. This study examined the expression pattern of TNFRSF12A in STAD and predicted immunotherapy response.MethodsData were de...

Full description

Saved in:
Bibliographic Details
Main Authors: Lin-De Sun, Lin-Lin Zhang, Zheng Wan, Xiao-Dong Yang, Jing Yao, Ze-Long Yang, Lin Liu, Jun-Yan Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1578068/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850279906098806784
author Lin-De Sun
Lin-Lin Zhang
Zheng Wan
Xiao-Dong Yang
Jing Yao
Ze-Long Yang
Lin Liu
Jun-Yan Liu
author_facet Lin-De Sun
Lin-Lin Zhang
Zheng Wan
Xiao-Dong Yang
Jing Yao
Ze-Long Yang
Lin Liu
Jun-Yan Liu
author_sort Lin-De Sun
collection DOAJ
description BackgroundTNFRSF12A is abnormally expressed in various malignancies, especially in stomach adenocarcinoma (STAD), which is related to tumor invasiveness and prognosis of patients. This study examined the expression pattern of TNFRSF12A in STAD and predicted immunotherapy response.MethodsData were derived from The Cancer Gene Atlas (TCGA), Gene Expression Omnibus (GEO), and Gene Expression Profiling Interactive Analysis (GEPIA) to analyze the expression pattern of TNFRSF12A in pan-cancer and STAD, as well as its correlation with clinical features. Biological pathways involved in TNFRSF12A were analyzed by “clusterProfiler” package. Immune cell infiltration was evaluated by “GSVA” and “CIBERSORT” packages. Immunotherapy response was assessed by TIDE score and tumor mutation burden (TMB) level. Expression level of TNFRSF12A in the single cell of STAD was analyzed by scRNA-seq. Finally, in vitro test detected the mRNA expression of TNFRSF12A in STAD cells, Wound healing and Transwell assays were performed to measure the capabilities of STAD cell to migrate and invade.ResultsTNFRSF12A was highly expressed in STAD. However, TNFRSF12A expression did not shown significant difference in relation to clinical features. TNFRSF12A exhibited notably positive correlation with many carcinogenic signaling pathways and immune cells infiltration such as T cells and macrophages. High TNFRSF12A expression group showed a higher TIDE score, Exclusion score, and TMB level than the low TNFRSF12A expression group, which indicated that STAD patients with high TNFRSF12A expression responded more poorly to immunotherapy. TNFRSF12A showed a positive relation with most of immune checkpoint genes. By scRNA-seq analysis, TNFRSF12A was chiefly expressed in Fibroblasts and Mast cells of STAD. Further, in vitro assays verified the high expression of TNFRSF12A in STAD cells, and the migration and invasion capabilities of STAD cells were notably suppressed by TNFRSF12A silencing (p<0.05).ConclusionThe present study not only reveals the potential of TNFRSF12A as a therapeutic target for STAD, but also explores its great potential in STAD immunotherapy. This finding opens up a new way of thinking for the personalized treatment of STAD.
format Article
id doaj-art-9b7e28d9d86c4c11919987befeca88d8
institution OA Journals
issn 1664-3224
language English
publishDate 2025-05-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj-art-9b7e28d9d86c4c11919987befeca88d82025-08-20T01:48:57ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-05-011610.3389/fimmu.2025.15780681578068TNFRSF12A expression in stomach adenocarcinoma and its preliminary role in predicting immunotherapy responseLin-De SunLin-Lin ZhangZheng WanXiao-Dong YangJing YaoZe-Long YangLin LiuJun-Yan LiuBackgroundTNFRSF12A is abnormally expressed in various malignancies, especially in stomach adenocarcinoma (STAD), which is related to tumor invasiveness and prognosis of patients. This study examined the expression pattern of TNFRSF12A in STAD and predicted immunotherapy response.MethodsData were derived from The Cancer Gene Atlas (TCGA), Gene Expression Omnibus (GEO), and Gene Expression Profiling Interactive Analysis (GEPIA) to analyze the expression pattern of TNFRSF12A in pan-cancer and STAD, as well as its correlation with clinical features. Biological pathways involved in TNFRSF12A were analyzed by “clusterProfiler” package. Immune cell infiltration was evaluated by “GSVA” and “CIBERSORT” packages. Immunotherapy response was assessed by TIDE score and tumor mutation burden (TMB) level. Expression level of TNFRSF12A in the single cell of STAD was analyzed by scRNA-seq. Finally, in vitro test detected the mRNA expression of TNFRSF12A in STAD cells, Wound healing and Transwell assays were performed to measure the capabilities of STAD cell to migrate and invade.ResultsTNFRSF12A was highly expressed in STAD. However, TNFRSF12A expression did not shown significant difference in relation to clinical features. TNFRSF12A exhibited notably positive correlation with many carcinogenic signaling pathways and immune cells infiltration such as T cells and macrophages. High TNFRSF12A expression group showed a higher TIDE score, Exclusion score, and TMB level than the low TNFRSF12A expression group, which indicated that STAD patients with high TNFRSF12A expression responded more poorly to immunotherapy. TNFRSF12A showed a positive relation with most of immune checkpoint genes. By scRNA-seq analysis, TNFRSF12A was chiefly expressed in Fibroblasts and Mast cells of STAD. Further, in vitro assays verified the high expression of TNFRSF12A in STAD cells, and the migration and invasion capabilities of STAD cells were notably suppressed by TNFRSF12A silencing (p<0.05).ConclusionThe present study not only reveals the potential of TNFRSF12A as a therapeutic target for STAD, but also explores its great potential in STAD immunotherapy. This finding opens up a new way of thinking for the personalized treatment of STAD.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1578068/fullTNFRSF12Asingle-cell RNA sequencingstomach adenocarcinomatumor microenvironmentimmunotherapy
spellingShingle Lin-De Sun
Lin-Lin Zhang
Zheng Wan
Xiao-Dong Yang
Jing Yao
Ze-Long Yang
Lin Liu
Jun-Yan Liu
TNFRSF12A expression in stomach adenocarcinoma and its preliminary role in predicting immunotherapy response
Frontiers in Immunology
TNFRSF12A
single-cell RNA sequencing
stomach adenocarcinoma
tumor microenvironment
immunotherapy
title TNFRSF12A expression in stomach adenocarcinoma and its preliminary role in predicting immunotherapy response
title_full TNFRSF12A expression in stomach adenocarcinoma and its preliminary role in predicting immunotherapy response
title_fullStr TNFRSF12A expression in stomach adenocarcinoma and its preliminary role in predicting immunotherapy response
title_full_unstemmed TNFRSF12A expression in stomach adenocarcinoma and its preliminary role in predicting immunotherapy response
title_short TNFRSF12A expression in stomach adenocarcinoma and its preliminary role in predicting immunotherapy response
title_sort tnfrsf12a expression in stomach adenocarcinoma and its preliminary role in predicting immunotherapy response
topic TNFRSF12A
single-cell RNA sequencing
stomach adenocarcinoma
tumor microenvironment
immunotherapy
url https://www.frontiersin.org/articles/10.3389/fimmu.2025.1578068/full
work_keys_str_mv AT lindesun tnfrsf12aexpressioninstomachadenocarcinomaanditspreliminaryroleinpredictingimmunotherapyresponse
AT linlinzhang tnfrsf12aexpressioninstomachadenocarcinomaanditspreliminaryroleinpredictingimmunotherapyresponse
AT zhengwan tnfrsf12aexpressioninstomachadenocarcinomaanditspreliminaryroleinpredictingimmunotherapyresponse
AT xiaodongyang tnfrsf12aexpressioninstomachadenocarcinomaanditspreliminaryroleinpredictingimmunotherapyresponse
AT jingyao tnfrsf12aexpressioninstomachadenocarcinomaanditspreliminaryroleinpredictingimmunotherapyresponse
AT zelongyang tnfrsf12aexpressioninstomachadenocarcinomaanditspreliminaryroleinpredictingimmunotherapyresponse
AT linliu tnfrsf12aexpressioninstomachadenocarcinomaanditspreliminaryroleinpredictingimmunotherapyresponse
AT junyanliu tnfrsf12aexpressioninstomachadenocarcinomaanditspreliminaryroleinpredictingimmunotherapyresponse